<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980210</url>
  </required_header>
  <id_info>
    <org_study_id>2018_63</org_study_id>
    <secondary_id>2019-A00053-54</secondary_id>
    <nct_id>NCT03980210</nct_id>
  </id_info>
  <brief_title>Effect of Hyperbaric Oxygen Therapy on Microcirculation</brief_title>
  <acronym>MICROHB</acronym>
  <official_title>Effect of Hyperbaric Oxygen Therapy on Healthy Volunteers Microcirculation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies shoes that hyperoxia alters microcirculation.The investigators hypothesize&#xD;
      that hyperbaric may restore microcirculation integrity. This hypothesis is supported by a&#xD;
      recent study in rabbits, but no data exists for humans.&#xD;
&#xD;
      The study will expose fifteen healthy volunteers to a succession of different fraction of&#xD;
      inspired oxygen and barometric pressure and assess microcirculatory and macrocirculatory&#xD;
      changes via sidestream dark field videomicroscopy, near-infrared spectroscopy, Laser Doppler,&#xD;
      transthoracic echocardiography and bio-impedancemetry at every step.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Microcirculation alterations and hyperoxia are known to alter ICU-patients' prognostic.&#xD;
&#xD;
      Studies have shown that hyperoxia alters healthy volunteers' microcirculation, whereas&#xD;
      hyperbaric oxygen therapy is commonly used to facilitate cicatrization. There seems to be a&#xD;
      paradox. A recent study in rabbits has given some evidences that hyperbaria may restore&#xD;
      microcirculation integrity, but to date, there is no such evidences in human.&#xD;
&#xD;
      To study hyperoxia and hyperbaric induced changes in micro and macrocirculation, fifteen&#xD;
      healthy volunteers will be exposed to successive variations of inspired oxygen fraction and&#xD;
      barometric pressure according to a predefine sequence so that only one parameter will change&#xD;
      from a condition to the next one :&#xD;
&#xD;
        1. FiO2 0.21 - 1 ATA&#xD;
&#xD;
        2. FiO2 1 - 1 ATA&#xD;
&#xD;
        3. FiO2 1 - 2.5 ATA&#xD;
&#xD;
        4. FiO2 0.21 - 2.5 ATA&#xD;
&#xD;
        5. FiO2 0.21 - 1 ATA&#xD;
&#xD;
      At each time, and after a 30 minutes period of exposure, measures will be made using&#xD;
      SDF-microscopy, Laser Doppler and NIRS to assess microcirculation.&#xD;
&#xD;
      As previously described, macrocirculation can modify microcirculation due to a mechanism&#xD;
      called hemodynamic coherence.&#xD;
&#xD;
      Hence, the investigators planned to assess macrocirculation changes at every step of the&#xD;
      protocol using bioimpedancemetry and transthoracic echocardiography.&#xD;
&#xD;
      Each volunteer will be his own control, using the first measurements (condition 1. FiO2 0.21&#xD;
      - 1 ATA) as reference.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Actual">July 25, 2019</completion_date>
  <primary_completion_date type="Actual">July 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in proportion of perfused vessel (PPV)</measure>
    <time_frame>30 minutes after hyperbaric hyperoxia exposure (FiO2 1 - 2.5 ATA)</time_frame>
    <description>Proportion of perfused vessel assessed by Sidestream dark field microscopy on the sublingual mucosa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in proportion of perfused vessel (PPV)</measure>
    <time_frame>30 minutes after FiO2 1 - 1 ATA exposure</time_frame>
    <description>Proportion of perfused vessel assessed by Sidestream dark field microscopy on the sublingual mucosa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in proportion of perfused vessel (PPV)</measure>
    <time_frame>30 minutes after FiO2 0.21 - 2.5 ATA exposure</time_frame>
    <description>Proportion of perfused vessel assessed by Sidestream dark field microscopy on the sublingual mucosa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hyperemic reaction after a vaso-occlusion test</measure>
    <time_frame>30 minutes after FiO2 1 - 2.5 ATA exposure</time_frame>
    <description>Area under curve assessed by near-infrared spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in area of hyperaemia after a vaso-occlusion test</measure>
    <time_frame>30 minutes after FiO2 1 - 2.5 ATA exposure</time_frame>
    <description>Area under curve assessed by Laser-Doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validation of cardiac output assessed by bioimpedancemetry under hyperbaric condition</measure>
    <time_frame>30 minutes after FiO2 1 - 2.5 ATA exposure</time_frame>
    <description>Comparison with transthoracic echocardiography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hyperbaric Oxygen Therapy</condition>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Successive changes in fraction of inspired oxygen and barometric pressure (ATA: Atmosphere absolute)&#xD;
Five successive steps:&#xD;
FiO2 0.21 - 1 ATA&#xD;
FiO2 1 - 1 ATA&#xD;
FiO2 1 - 2.5 ATA&#xD;
FiO2 0.21 - 2.5 ATA&#xD;
FiO2 0.21 - 1 ATA</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperbaric oxygen therapy</intervention_name>
    <description>FiO2 0.21 - 1 ATA&#xD;
FiO2 1 - 1 ATA&#xD;
FiO2 1 - 2.5 ATA&#xD;
FiO2 0.21 - 2.5 ATA&#xD;
FiO2 0.21 - 1 ATA</description>
    <arm_group_label>Hyperbaric oxygen therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  To provide a medical certificate of fitness to dive (&lt; 1 year)&#xD;
&#xD;
          -  Consent given for study participation&#xD;
&#xD;
          -  French health insurance affiliated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Temporary or definitive contra-indication to dive&#xD;
&#xD;
          -  Pregnancy or &lt; 18 years of age&#xD;
&#xD;
          -  Precedent dive &lt; 24 hours&#xD;
&#xD;
          -  Under a legal protection measure&#xD;
&#xD;
          -  Medical history of a disease known to alter microcirculation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thibault Duburcq, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HÃ´pital Roger Salengro, CHU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperbaric oxygen therapy</keyword>
  <keyword>Normobaric oxygen therapy</keyword>
  <keyword>Hyperoxia</keyword>
  <keyword>Sidestream dark field videomicroscopy</keyword>
  <keyword>Microcirculation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

